Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
First Patient Enrolls in 18F-OP-801 Phase 1/2 Neurological Imaging Trial
Pharma Pioneer
2 min read
First Patient Enrolls in 18F-OP-801 Phase 1/2 Neurological Imaging Trial
22 May 2024
Ashvattha Therapeutics has enrolled its first patient in an expanded Phase 1/2 trial of 18F-OP-801, an imaging agent designed to cross the blood-brain barrier and target neuroinflammation.
Read →
OncoC4 Initiates Phase 1/2 Trial of BNT316/ONC-392 for Advanced Prostate Cancer Patients
Pharma Pioneer
3 min read
OncoC4 Initiates Phase 1/2 Trial of BNT316/ONC-392 for Advanced Prostate Cancer Patients
22 May 2024
A clinical trial is currently underway to evaluate the combination treatment of BNT316/ONC-392, an anti-CTLA-4 antibody, with lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).
Read →
Ocugen Completes Dosing in Phase 1/2 Stargardt Clinical Trial for OCU410ST Gene Therapy
Pharma Pioneer
2 min read
Ocugen Completes Dosing in Phase 1/2 Stargardt Clinical Trial for OCU410ST Gene Therapy
22 May 2024
Biotechnology firm Ocugen, Inc. has reached a significant milestone in its clinical trial for a gene therapy treatment, OCU410ST, aimed at Stargardt disease.
Read →
First Patient Receives Gedatolisib in Phase 1b/2 Trial for mCRPC Treatment
Pharma Pioneer
2 min read
First Patient Receives Gedatolisib in Phase 1b/2 Trial for mCRPC Treatment
22 May 2024
Biotechnology firm Celcuity Inc. has initiated a Phase 1b/2 clinical trial, known as CELC-G-201, to test the efficacy and safety of gedatolisib combined with Nubeqa® (darolutamide).
Read →
Elevation Oncology Initiates Global Expansion of EO-3021 Phase 1 Trial with First Japanese Patient Dosing
Pharma Pioneer
2 min read
Elevation Oncology Initiates Global Expansion of EO-3021 Phase 1 Trial with First Japanese Patient Dosing
22 May 2024
Elevation Oncology, a company listed on the Nasdaq (ELEV), is advancing its Phase 1 clinical trial for EO-3021, a novel antibody drug conjugate (ADC), by expanding the study to include Japan.
Read →
Unseen Challenges: The Quest for LGBTQIA+ Inclusivity in Patient Data
Pharma Pioneer
3 min read
Unseen Challenges: The Quest for LGBTQIA+ Inclusivity in Patient Data
22 May 2024
The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.
Read →
PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
Pharma Pioneer
2 min read
PPTI Launches Phase I Trial for Zolmitriptan Microporation System in Migraine Treatment
22 May 2024
San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.
Read →
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
Pharma Pioneer
2 min read
Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years
22 May 2024
AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.
Read →
Biodexa Reports Favorable Phase I DMG Trial Outcomes and R&D Progress
Pharma Pioneer
2 min read
Biodexa Reports Favorable Phase I DMG Trial Outcomes and R&D Progress
22 May 2024
Biodexa Pharmaceuticals PLC has reported encouraging preliminary results from a Phase I clinical trial for MTX110.
Read →
Frontier Medicines Secures $80M for KRAS Inhibitor Development, Challenges Amgen and BMS
Pharma Pioneer
2 min read
Frontier Medicines Secures $80M for KRAS Inhibitor Development, Challenges Amgen and BMS
22 May 2024
Frontier Medicines recently closed an $80 million Series C funding round, with plans to advance its novel KRAS blocker, FMC-376.
Read →
JIN-A02: 4th Gen EGFR TKI Phase 1/2 Study for NSCLC Accepted at AACR 2024
Pharma Pioneer
2 min read
JIN-A02: 4th Gen EGFR TKI Phase 1/2 Study for NSCLC Accepted at AACR 2024
22 May 2024
J INTS BIO has announced that the Phase 1/2 clinical trial of its new oral 4th generation EGFR TKI, named "JIN-A02," for treating non-small cell lung cancer (NSCLC).
Read →
AceLink Therapeutics Publishes Positive Phase 1 AL01211 Trial Results in Healthy Subjects
Pharma Pioneer
2 min read
AceLink Therapeutics Publishes Positive Phase 1 AL01211 Trial Results in Healthy Subjects
22 May 2024
AceLink Therapeutics has reported positive preliminary findings for AL01211, an oral medication being developed to treat Fabry and Type 1 Gaucher diseases.
Read →